600 patients66,869 observations120 daysLIVE

Patient P-01473

Synthetic patientNBL-101 · Day 119 · 75+ · F · baseline S14Steering view · 3DOpen companion preview
Therapy response
Stable
Tolerance
Improving
GI state
Stable
Inflammatory state
Improving
Nutritional resilience
Stable
Discontinuation risk
62%

Trajectory

Baseline → today → 30-day prediction · hover a day for signals and events
solid = observed · dashed = predicted
  1. Day 0 NBL-101 startedBaseline state S14
  2. Day 46 Trajectory diverged from predictionObserved response fell below the model's expected path.
  3. Day 52 SC-12 recommendedSupportive Compound SC-12
  4. Day 53 Patient acceptedStarted SC-12 in the companion
  5. Day 56 GI-04 recommendedGI Support Protocol GI-04
  6. Day 57 Patient acceptedStarted GI-04 in the companion
  7. Day 59 GI symptom burden −16% vs expectedSupportive Compound SC-12
  8. Day 65 GI symptom burden −21% vs expectedGI Support Protocol GI-04
  9. Day 65 Tolerance state changedUnstable → Improving
  10. Day 71 Tolerance state changedUnstable → Improving

What changed?

Trajectory began diverging from predicted response on Day 46.

Primary contributors, last 14 days
  • Toxicity-9
  • Inflammatory activity-5
  • GI instability-2
  • Nutritional resilience+2

What helped?

  • Supportive Compound SC-12Day 52
    Result: symptom burden −16%
  • GI Support Protocol GI-04Day 56
    Result: symptom burden −21%
LIFE OS recommendation
Dietary Support Protocol NP-02
53%
probability of meaningful tolerance improvement
  • 284 similar trajectories
  • 66% showed improvement
  • median effect visible after 10 days

Daily trackers

Molecule settings

The trackers this program marks as important, last 14 days vs the 14 before.

GI burden
Companion
49.4/100
worsening · +4.4 vs previous 14 d
Toxicity
Blood
40/100
stable · +0.8 vs previous 14 d
Sleep quality
Wearable
44.7/100
worsening · -6.4 vs previous 14 d
Energy level
Daily log
3.3/10
worsening · -0.2 vs previous 14 d
Stress level
Daily log
6.5/10
worsening · +0.5 vs previous 14 d
Steps
Wearable
3,821
improving · +197 vs previous 14 d
Adherence
Companion
51.4 %
stable · +1.5 vs previous 14 d
This trajectory is decaying — what would help, what would not
Steering view →

Heading towards restoration · 39 from the failing basin, 49 from restoration.

Would help
  • ME-01 Monitoring Escalation
    100% improved among 77 similar · onset 3 d · confidence 62%
  • NP-02 Dietary Support Protocol
    63% improved among 64 similar · onset 10 d · confidence 62%
  • CR-01 Clinician Review
    100% improved among 8 similar · onset 5 d · confidence 62%
Would not help
  • Keep fat low
    GI +4.8 next day on high-intake days · n 22
  • Keep histamine low
    GI +3.9 next day on high-intake days · n 21
State influencers · digestive

Next-day GI change on high-intake vs low-intake days, last 60 days. Attribution from this patient's own log; sensitivity set by their biology.

  • Dietary fat load
    +4.8detractor · 95%
  • Histamine load
    +3.9detractor · 95%
  • Alcohol
    -1.5no signal · 30%
  • Insoluble fibre
    -0.5no signal · 15%
  • Simple carbohydrates
    +0.4no signal · 15%
  • Spicy / capsaicin
    +0.4no signal · 15%

Biological layers

Which pathways look influenced, and by which layer of this person's biology.

Pathways under pressure
  • Mucosal barrier integrity 80
    • DNAFUT2 non-secretor lowers mucosal fucosylation
    • MicrobiomeAkkermansia low → thinner mucus layer
    • Daily logGI symptom score 49 and rising
  • Butyrate / short-chain fatty acid production 80
    • MicrobiomeButyrate capacity 33/100
    • MicrobiomeF. prausnitzii depleted
    • Daily logFibre intake low in recent food logs
  • Inflammatory signalling 60
    • MicrobiomeBacteroides fragilis expansion
    • BloodInflammatory load index 48
    • WearableHRV 38 ms, trending down
  • Autonomic recovery 20
    • Wearable3,821 steps/day
DNA
Fictional pharmacogenomic panel
  • FUT2 rs601338 AA (non-secretor)
    Reduced mucosal fucosylation
  • CYP2D6 Normal metabolizer
    Expected exposure
Microbiome
Shannon diversity 3.1 · butyrate capacity 33/100
  • Akkermansia muciniphilaLow
  • Faecalibacterium prausnitziiLow
  • Bacteroides fragilisHigh
  • Bifidobacterium longumLow
  • EnterobacteriaceaeNormal
Wearable, last 14 days
daily evolution fed into the runtime
HRV
40 ms
Sleep
6.7 h
Steps
3,859
Resting HR
70 bpm
Daily log: GI score 49, nutritional resilience 44, adherence 51.

What this patient sees in NostraAI

The content that steers the trajectory: what to eat, what to do, what to take.

Open companion preview
What to eat
  • Prepare a plain, low-fat pasta or rice meal and note how it feels afterwards
  • Choose a freshly cooked, lean protein; avoid frying, rich sauces and leftovers for now
  • Add one soluble-fibre source (oats, cooked carrots, banana) to breakfast
  • Avoid known triggers for now: fried or oily food, dairy, alcohol
What to do
  • Track each bowel movement today: time, stool form, urgency, overnight waking
  • A 15-minute walk after lunch
  • Keep the sleep window steady
  • Keep hydration steady: small amounts through the day rather than large volumes at once
What to take
  • Take the scheduled dose as agreed with your care team
  • Electrolyte solution, one sachet after any loose stool
  • Fictional demo item: oral nutrition supplement with lunch

284 biologically similar trajectories

Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.

PatientSimilarityBaselineInterventionOutcomeResponse today
P-0160424%S0171
P-0138624%S1370
P-0135223%S2070
P-0175024%S1669
P-0169929%S04GI-04improved69
P-0150824%S1868
P-0150926%S1768
P-0187524%S1167
P-0181725%S1467
P-0187727%S01CR-01improved67
P-0162925%S1966
P-0171434%S14GI-04improved66